When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Chronic myeloid leukemia

Última revisão: 18 Jun 2025
Última atualização: 29 Nov 2024

Resumo

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • splenomegaly
  • shortness of breath
  • left upper quadrant discomfort or fullness
  • epistaxis
  • arthralgia
  • sternal tenderness
Полная информация

Другие диагностические факторы

  • weight loss
  • excessive sweating
  • fever
  • pallor
  • bruising
  • retinal hemorrhages
Полная информация

Факторы риска

  • age 65 to 74 years
  • ionizing radiation exposure
  • male sex
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • CBC
  • complete metabolic profile
  • peripheral blood smear
  • bone marrow aspirate and biopsy for cytogenetic analysis
  • quantitative reverse transcription PCR (qRT-PCR) including breakpoint analysis
  • fluorescence in situ hybridization (FISH)
Полная информация

Исследования, проведение которых нужно рассмотреть

  • mutational analysis
Полная информация

Алгоритм лечения

Острый

chronic phase

accelerated phase

Составители

Авторы

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Leukemia Service

Attending Physician and Member

Memorial Sloan Kettering Cancer Center

Professor, Weill Cornell Medicine

New York

NY

Раскрытие информации

MJM has received institutional research support for clinical trials from Novartis, Bristol Myers Squibb, Takeda, and Sun Pharma/Sparc, and honoraria for consulting/advisory boards from Novartis, Bristol Myers Squibb, Takeda, and Pfizer.

Выражение благодарностей

Dr Michael Mauro would like to gratefully acknowledge Dr Tim Somervaille, Dr Han Myint, and Dr Robert Chen, the previous contributors to this topic.

Раскрытие информации

TS has received travel support and speaker expenses from Novartis, and has served as a consultant to Novartis for development of drugs for indications other than CML. HM sits on the advisory board of Novartis and Bristol Myers Squibb, and also does speaking engagements on their behalf. RC declares that he has no competing interests.

Рецензенты

Rebecca Connor, MD

Chief Fellow

Section of Hematology and Oncology

Department of Internal Medicine

Wake Forest University Baptist Medical Center

Winston-Salem

NC

Раскрытие информации

RC declares that she has no competing interests.

Richard E. Clark, MA, MD, FRCP, FRCPath

Professor of Haematology

Royal Liverpool University Hospital

Liverpool

UK

Раскрытие информации

None disclosed.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Полный текст

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Полный текст  Аннотация

Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Полный текст  Аннотация

Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности